Denne side blev automatisk oversat, og nøjagtigheden af ​​oversættelsen er ikke garanteret. Der henvises til engelsk version for en kildetekst.

Observational Study to Evaluate the Clinical Impact of BTK Inhibitor-Based Regimens in Treatment-Naïve Patients With Mantle Cell Lymphoma (MCL) in Italian Clinical Practice.

9. november 2026 opdateret af: Fondazione Italiana Linfomi - ETS

An Observational Cohort Study to Evaluate the Clinical Impact of BTK Inhibitor-Based Regimens in Treatment-Naïve Patients With Mantle Cell Lymphoma (MCL) in Italian Clinical Practice.

Mantle cell lymphoma (MCL) is a subtype of B-cell non-Hodgkin lymphoma (B-NHL), characterized by a heterogeneous clinical course and, in a substantial proportion of patients, an aggressive disease behavior requiring timely and effective treatment at diagnosis.

In recent years, the therapeutic landscape of MCL has undergone a major transformation with the introduction of Bruton's tyrosine kinase inhibitors (BTKis). Ibrutinib, acalabrutinib, zanubrutinib, and the non-covalent BTKi pirtobrutinib have demonstrated substantial clinical activity in relapsed/refractry (R/R) MCL. Their role has progressively expanded beyond the relapsed/refractory setting, with BTK inhibitor-based regimens increasingly being incorporated into frontline treatment strategies, supported by emerging clinical trial evidence and reflected in evolving treatment guidelines and clinical practice.

Despite this rapidly evolving treatment landscape, real-world evidence on the use of BTKi-based regimens in the frontline setting remains limited. In particular, data on treatment selection, efficacy, safety, treatment duration, and management of toxicities in routine clinical practice are still scarce.

We therefore propose an observational cohort study to evaluate the clinical impact of previously untreated patients with MCL receiving frontline BTKi-based regimens in routine clinical practice in Italy. The study will assess treatment patterns, effectiveness, safety, and treatment persistence, providing real-world insights into the use of these strategies beyond clinical trials.

Studieoversigt

Status

Ikke rekrutterer endnu

Betingelser

Undersøgelsestype

Observationel

Tilmelding (Anslået)

500

Kontakter og lokationer

Dette afsnit indeholder kontaktoplysninger for dem, der udfører undersøgelsen, og oplysninger om, hvor denne undersøgelse udføres.

Studiekontakt

Undersøgelse Kontakt Backup

Deltagelseskriterier

Forskere leder efter personer, der passer til en bestemt beskrivelse, kaldet berettigelseskriterier. Nogle eksempler på disse kriterier er en persons generelle helbredstilstand eller tidligere behandlinger.

Berettigelseskriterier

Aldre berettiget til at studere

18 år og ældre (Voksen, Ældre voksen)

Tager imod sunde frivillige

Ingen

Køn, der er berettiget til at studere

Alle

Prøveudtagningsmetode

Ikke-sandsynlighedsprøve

Studiebefolkning

Previously untreated patients with Mantle Cell Lymphoma receiving frontline Bruton's Tyrosin Kinase-based treatment in routine clinical practice in Italy.

Beskrivelse

Inclusion criteria:

General Inclusion Criteria:

  • Histologically confirmed diagnosis of mantle cell lymphoma (MCL) requiring treatment according to current clinical guidelines and standard-of-care recommendations.
  • Age ≥ 18 years at the time of BTKi-based treatment initiation.
  • Patients who are able to understand the nature and objectives of the study and who have provided written informed consent, approved by the Independent Ethics Committee (IEC), for participation in the observational study.

For the retrospective enrollment group:

In addition to the general inclusion criteria, patients included in the retrospective cohort must meet the following criterion:

● Patients eligible for BTKi-based treatment before the relevant marketing authorization (AIC) in Italy, includingthose treated through off-label use, compassionate use programs, or under Italian Law 648/96, as applicable.

For the prospective enrollment group:

In addition to the general inclusion criteria, patients included in the prospective cohort must meet the following criterion:

● Patients eligible for a BTKi-based regimen in accordance with the EMA-approved indication and the corresponding AIC in Italy.

Exclusion criteria:

  • Diagnosis of a histological subtype of lymphoma other than mantle cell lymphoma (MCL).
  • Concurrent participation in a prospective interventional clinical trial that may interfere with the assessment of treatment exposure, efficacy, safety, or other study endpoints.
  • Inability or unwillingness to provide written informed consent, where required by applicable ethical and regulatory requirements.
  • Any condition that, in the investigator's judgment, may preclude reliable collection or interpretation of study data or compromise the patient's ability to participate in the study.

Studieplan

Dette afsnit indeholder detaljer om studieplanen, herunder hvordan undersøgelsen er designet, og hvad undersøgelsen måler.

Hvordan er undersøgelsen tilrettelagt?

Design detaljer

  • Observationsmodeller: COHORT
  • Tidsperspektiver: CROSS_SECTIONAL

Kohorter og interventioner

Gruppe / kohorte
Retrospective enrollment group

Patients who had an indication for a BTKi-based regimen before the marketing authorization (AIC) in Italy. This group may include patients treated before the relevant AIC through off-label use, compassionate use programs, or treatment provided under Italian Law 648/96.

Prospective enrollment group

Patients eligible for a BTKi-based regimen in accordance with the EMA approved indication and the corresponding AIC in Italy.

Hvad måler undersøgelsen?

Primære resultatmål

Resultatmål
Foranstaltningsbeskrivelse
Tidsramme
Best overall response
Tidsramme: From the beginning of the study up to 5 years after last enrolled patient (up 15 years from study beginning)

Defined according to Lugano 2014 criteria as the best response recorded between the start of therapy and the end of treatment. Overall response rate (ORR) includes complete (CR) and partial response (PR). Patients without response assessment for any reason are considered non-responders.

From the beginning of the study up to 5 years after last enrolled patient (up 15 years from study beginning)
Progression-free survival (PFS)
Tidsramme: From the beginning of the study up to 5 years after last enrolled patient (up 15 years from study beginning)

Defined as the time from the start of BTKi-based treatment to the first documentation of relapse, progression or death from any cause. Patients alive without progression are censored at the date of last disease assessment.

From the beginning of the study up to 5 years after last enrolled patient (up 15 years from study beginning)
Overall survival (OS)
Tidsramme: From the beginning of the study up to 5 years after last enrolled patient (up 15 years from study beginning)

Defined as the time from the start of BTKi-based treatment to death from any cause. Patients alive are censored at the date of last contact.

From the beginning of the study up to 5 years after last enrolled patient (up 15 years from study beginning)
Event-free survival (EFS)
Tidsramme: From the beginning of the study up to 5 years after last enrolled patient (up 15 years from study beginning)

Defined as the time from the start of BTKi-based treatment to progression, death from any cause or initiation of a new anti-lymphoma treatment (NALT) without documented progression.

From the beginning of the study up to 5 years after last enrolled patient (up 15 years from study beginning)
Time to next treatment (TTNT)
Tidsramme: From the beginning of the study up to 5 years after last enrolled patient (up 15 years from study beginning)

Defined as the time from the start of BTKi-based treatment to the initiation of a NALT.

From the beginning of the study up to 5 years after last enrolled patient (up 15 years from study beginning)
Duration of response (DOR)
Tidsramme: From the beginning of the study up to 5 years after last enrolled patient (up 15 years from study beginning)

Defined in responding patients as the time from the first documentation of CR or PR to progression or death from any cause

From the beginning of the study up to 5 years after last enrolled patient (up 15 years from study beginning)
Non-relapse mortality (NRM)
Tidsramme: From the beginning of the study up to 5 years after last enrolled patient (up 15 years from study beginning)

Defined as death without prior relapse or progression

From the beginning of the study up to 5 years after last enrolled patient (up 15 years from study beginning)
POD24
Tidsramme: From the beginning of the study up to 5 years after last enrolled patient (up 15 years from study beginning)

Defined as relapse or progression within 24 months from diagnosis (early POD) or later than 24 months (late POD)

From the beginning of the study up to 5 years after last enrolled patient (up 15 years from study beginning)
Incidence of adverse events
Tidsramme: From the beginning of the study up to 5 years after last enrolled patient (up 15 years from study beginning)

Incidence of grade 3, 4 and 5 adverse events according to the latest NCI CTCAE version, and of serious adverse events, occurring after the first dose or at any time during therapy.

From the beginning of the study up to 5 years after last enrolled patient (up 15 years from study beginning)
Incidence of deaths
Tidsramme: From the beginning of the study up to 5 years after last enrolled patient (up 15 years from study beginning)

Deaths occurring during treatment, at the end of treatment, and during follow-up, with specific assessment of early deaths (defined as deaths occurring within 3 months from treatment initiation), treatment-related (toxic) deaths, and causes of death (any).

From the beginning of the study up to 5 years after last enrolled patient (up 15 years from study beginning)

Sekundære resultatmål

Resultatmål
Foranstaltningsbeskrivelse
Tidsramme
Treatment duration
Tidsramme: From the beginning of the study up to 5 years after last enrolled patient (up 15 years from study beginning)

Defined as the time from the start of BTKi-based treatment to permanent discontinuation for any reason.

From the beginning of the study up to 5 years after last enrolled patient (up 15 years from study beginning)
Treatment discontinuation
Tidsramme: From the beginning of the study up to 5 years after last enrolled patient (up 15 years from study beginning)

Incidence and reasons for treatment discontinuation (progression, toxicity, death, patient preference, physician decision, planned completion, other).

From the beginning of the study up to 5 years after last enrolled patient (up 15 years from study beginning)
Treatment modifications
Tidsramme: From the beginning of the study up to 5 years after last enrolled patient (up 15 years from study beginning)

Frequency and reasons for dose reductions, interruptions and other modifications.

From the beginning of the study up to 5 years after last enrolled patient (up 15 years from study beginning)

Samarbejdspartnere og efterforskere

Det er her, du vil finde personer og organisationer, der er involveret i denne undersøgelse.

Sponsor

Efterforskere

  • Ledende efterforsker: Marco Ladetto, MD, S.C.D.U. Ematologia, I.R.C.C.S. A.O.U. SS. Antonio e Biagio e Cesare Arrigo - Alessandria

Datoer for undersøgelser

Disse datoer sporer fremskridtene for indsendelser af undersøgelsesrekord og resumeresultater til ClinicalTrials.gov. Studieregistreringer og rapporterede resultater gennemgås af National Library of Medicine (NLM) for at sikre, at de opfylder specifikke kvalitetskontrolstandarder, før de offentliggøres på den offentlige hjemmeside.

Studer store datoer

Studiestart (Anslået)

1. marts 2027

Primær færdiggørelse (Anslået)

1. marts 2042

Studieafslutning (Anslået)

1. marts 2042

Datoer for studieregistrering

Først indsendt

9. november 2026

Først indsendt, der opfyldte QC-kriterier

9. november 2026

Først opslået (Faktiske)

16. november 2026

Opdateringer af undersøgelsesjournaler

Sidste opdatering sendt (Faktiske)

16. november 2026

Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier

9. november 2026

Sidst verificeret

1. november 2026

Mere information

Begreber relateret til denne undersøgelse

Andre undersøgelses-id-numre

  • FIL_MANTLE-FIRST-BTKi

Lægemiddel- og udstyrsoplysninger, undersøgelsesdokumenter

Studerer et amerikansk FDA-reguleret lægemiddelprodukt

Ingen

Studerer et amerikansk FDA-reguleret enhedsprodukt

Ingen

Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .